Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

JAK inhibitors are effective for long-term management of alopecia areata.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Rituximab may cause skin issues, but baricitinib can help improve them.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Micelles can change cetirizine's ionization, affecting its effectiveness in treatments.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

New treatments like JAK inhibitors offer hope for better alopecia areata management.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

CTP-543 is generally safe for treating alopecia areata.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Afatinib often causes skin problems that need proactive management.